By Tony Fong
NEW YORK (GenomeWeb News) – Having demonstrated the utility of its technology, molecular diagnostics firm Sequenta will focus on clinical validation of its technology in 2012 with an expected launch of its first product next year.
Registering provides access to this and other free content.
Already have an account?Login Now.
The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.
Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.
Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.
In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.